New Virtual Screening Strategy Identifies Existing Drug that Inhibits COVID-19 Virus

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China, and colleagues present these findings in the open-access journal PLOS Computational Biology.

With the COVID-19 pandemic causing illness and death worldwide, better treatments are urgently needed. One shortcut could be to repurpose existing drugs that were originally developed to treat other conditions. Computational methods can help identify such drugs by simulating how different drugs would interact with SARS-CoV-2, the virus that causes COVID-19.

To aid virtual screening of existing drugs, Zhang and colleagues combined multiple computational techniques that simulate drug-virus interactions from different, complimentary perspectives. They used this hybrid approach to screen 1,906 existing drugs for their potential ability to inhibit replication of SARS-CoV-2 by targeting a viral protein called RNA-dependent RNA polymerase (RdRP).

The novel screening approach identified four promising drugs, which were then tested against SARS-CoV-2 in lab experiments. Two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus. Further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir, a drug that is currently used to treat some COVID-19 patients.

These findings suggest that pralatrexate could potentially be repurposed to treat COVID-19. However, this chemotherapy drug can prompt significant side effects and is used for people with terminal lymphoma, so immediate use for COVID-19 patients is not guaranteed. Still, the findings support the use of the new screening strategy to identify drugs that could be repurposed.

"We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics," Zhang says. He and his colleagues are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat COVID-19.

Zhang H, Yang Y, Li J, Wang M, Saravanan KM, Wei J, et al.
A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.
PLoS Comput Biol 16(12), 2020. doi: 10.1371/journal.pcbi.1008489

Most Popular Now

Senior Nurse adds to Clinical Expertise …

A senior nurse with more than 20 years' experience in the NHS has joined smart health tech provider Alcidion in a core role as a clinical consultant primarily working with...

Wearable Devices can Detect COVID-19 Sym…

Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first...

Philips completes the acquisition of Bio…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that it has completed the acquisition of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote...

Siemens Healthineers and Kantonsspital B…

Siemens Healthineers and the Kantonsspital Baden (KSB) in Switzerland, a networked, regional center of competence, have formed a long-term, strategic and technological partnership for the next eight years. This "Value...

A Machine-Learning Approach to Finding T…

When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes forever," says Caroline Uhler...

Medway Picks Allscripts Sunrise EPR to M…

Medway NHS Foundation Trust is looking to make rapid improvements in its digital maturity with the Allscripts Sunrise electronic patient record. The Kent trust signed a contract with Allscripts in December...

Computational Medicine - Moving from Unc…

Individual choices in medicine carry a certain amount of uncertainty. An innovative partnership at The University of Texas at Austin takes aim at medicine down to the individual level by applying...

26,000 Falls may Have Been Prevented aft…

Greater scrutiny in prescribing amongst elderly patients may have prevented 26,000 falls in a single year, according to new analysis by Kent Surrey Sussex Academic Health Science Network (KSS AHSN). The...

Location Tracking Apps and Privacy Impli…

How much personal information can our phone apps gather through location tracking? To answer this question, two researchers - Mirco Musolesi (University of Bologna, Italy) and Benjamin Baron (University College...

Cybersecurity in Healthcare: HubIT Final…

17 February 2021, Online. The online international workshop "Cybersecurity within Healthcare Systems" takes place on the 17 of February 2021 from 10-13 am CET. The aim of this workshop is to...

How to Make the Most of Your Virtual Hea…

With virtual medical appointments becoming more popular amid physical distancing measures, an expert from a top American hospital, Cleveland Clinic, has advice on what conditions are suitable for virtual visits...

Visionable Appoints First CCO Following …

British health technology company Visionable has announced the appointment of David Walker to the newly created position of Chief Commercial Officer (CCO), effective immediately. Visionable redesigns healthcare through a digital...